- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05951803
Effectiveness of a Psychological Intervention on Mental Health and Sleep.
July 10, 2023 updated by: Horacio Balam ALvarez Garcia, Hospital General de Mexico
Effectiveness of the Brief Behavioral Intervention for Insomnia in the Teleconsultation Modality (ICBI-TC) on the Symptoms of Anxiety, Depression, Sleep Quality and Quality of Life in Insomniac Patients.
Background: The COVID-19 pandemic represented a global public health problem that brought considerable consequences to the physical and mental health of the entire population.
Objective: To compare the effectiveness of the brief behavioral intervention for insomnia by teleconsultation (BBII-TC) with the brief behavioral intervention for face-to-face insomnia (BBII) on symptoms of insomnia, anxiety, depression, quality of sleep and life in a sample. of patients with long COVID.
Methodology: Randomized controlled trial of equivalence with two groups in parallel (1:1) with repeated measures in pretreatment, posttreatment and follow-up at 3 months.
The sample will be composed of male or female participants, in an age range of 18 to 40 years.
The sample size was calculated, obtaining a total of 52 participants, the expected effect size is .40,
with a significance of 0.05 and a probability error of 80%.
Participants in the two groups will be assessed with the following instruments: Sleep Diary, Patient Health Questionnaire 9, Pittsburgh Sleep Quality Index , Insomnia Severity Index, SF-36 Health Survey and Generalized Anxiety Disorder 7; at the beginning and end of treatment; and in a follow-up at 3 months.
TData analysis: The Kolmogrov-Smirnov test will be carried out to determine the normality of the data, in case the distribution is parametric, an ANOVA of repeated measures will be carried out for the comparison of data between the pre, post and monitoring for each of the groups; in the event that the data does not have a normal distribution, the Friedman test will be performed for the comparison of repeated measures.
Finally, to avoid bias in the data analysis, an external investigator will be asked to perform the randomization and data processing.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
Once the sample is composed, the participants will be randomized in a simple computerized way to one of the two groups.
A structured clinical interview will be carried out, then they will be given the sleep diary and the instruments will be applied to measure the degree of symptoms of sleep disorders.
Study Type
Interventional
Enrollment (Estimated)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mexico City, Mexico, 15300
- Horacio Balam Álvarez García
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have a personal pathological history of diagnosis of COVID-19 (mild or severe) by PCR test or antigen test in the last 6 months.
- Present symptoms of insomnia.
- Present anxiety symptoms.
- Present symptoms of depression.
- Be between 18 and 40 years old.
- Have digital devices such as a computer, tablet or smartphone with internet access.
Exclusion Criteria:
- Being in psychological or pharmacological treatment to control insomnia, anxiety, depression, at the time of the study.
- Presenting symptoms of another sleep disorder such as obstructive sleep apnea, restless legs syndrome, or sleep disorder due to work hours (1).
- Suffering from cardiorespiratory or neurological sequelae of COVID-19 do not allow the participant to take the treatment.
- Consume psychoactive substances of abuse (Cannabis, cocaine, solvents, cannabidiol).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Brief Behavioral Intervention in Insomnia through Tele-Consultation (BBII-TC)
Brief therapy organized into four sessions, lasting 60 minutes each, where behavioral therapy techniques are taught (stimulus control, sleep restriction, progressive muscle relaxation, sleep hygiene).
The teleconsultation modality is given through the ZOOM platform synchronously.
|
Weekly intervention of 4 sessions where behavior therapy techniques are administered, such as stimulus control, sleep hygiene, sleep restriction and progressive muscle relaxation.
Each session lasts 60 minutes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep diary
Time Frame: 1 week after starting treatment.
|
Self-registration format subjectively evaluates the number of sleepless nights, subjective sleep quality, number of awakenings per night, sleep onset latency, and sleep efficacy
|
1 week after starting treatment.
|
Patient Health Questionnaire 9 (PHQ-9)
Time Frame: 1 week after starting treatment.
|
Self-applied questionnaire that assesses the presence and severity of depressive symptoms.
It is made up of 9 items on a Likert scale that goes from 0 (not at all) to 3 (almost every day).
The evaluation consists of the sum of the scores of each item having a range of 0 to 27.
These scores are interpreted from 0 to 5 (mild), 6 to 10 (moderate), 11 to 15 (moderately severe) and 16 to 27. (severe).
Within its psychometric properties, the original version has a high internal consistency with a Cronbach's alpha of 0.86, while the Mexican version was 0.89.
|
1 week after starting treatment.
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 1 week after starting treatment.
|
Self-administered questionnaire that assesses sleep quality.
It is made up of 24 reagents; the total score has a range of 0 to 21 points; where a total score less than 5 points indicates good sleep quality and a score greater than 5 points is interpreted as poor sleep quality.
In the Mexican population, he obtained a Cronbach's Alpha of 0.78.
|
1 week after starting treatment.
|
Insomnia Severity Index (ISI)
Time Frame: 1 week after starting treatment.
|
Self-administered questionnaire of 8 items on a Likert scale from 0 (none) to 4 (Very severe), which assesses nighttime symptoms, sleep quality, and daytime symptoms of insomnia; it has a reliability of 0.82 in its original version; and it has similar psychometric indicators in a version validated in Spanish.
In its version for the Mexican population, it obtained a 0.84 reliability coefficient.
|
1 week after starting treatment.
|
SF-36 Health Survey
Time Frame: 1 week after starting treatment.
|
It is a self-applicable instrument that evaluates the quality of life of people, it is divided into 8 dimensions associated with health such as: physical function, physical role, bodily pain, general health, vitality, social function, emotional role and mental health.
Each of these dimensions is evaluated in a different way, being a Likert scale between 4 and 5 response options and dichotomous (yes/no) in others.
Within the Mexican version, the psychometric properties showed a high internal consistency with a Cronbach's alpha of 0.93.
|
1 week after starting treatment.
|
Generalized Anxiety Disorder 7 (GAD-7)
Time Frame: 1 week after starting treatment.
|
Self-administered questionnaire that assesses the presence and severity of generalized anxiety symptoms.
It is made up of 7 items on a Likert scale that goes from 0 (not at all) to 3 (almost every day).
The evaluation consists of the sum of the scores of each item having a range from 0 to 21.
It is interpreted that a score greater than 10 is considered as generalized anxiety.
Within its psychometric properties, the version translated into Spanish has a high internal consistency with a Cronbach's alpha of 0.8.
|
1 week after starting treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep diary
Time Frame: 4 weeks after starting treatment
|
Self-registration format subjectively evaluates the number of sleepless nights, subjective sleep quality, number of awakenings per night, sleep onset latency, and sleep efficacy
|
4 weeks after starting treatment
|
Patient Health Questionnaire 9 (PHQ-9)
Time Frame: 4 weeks after starting treatment
|
Self-applied questionnaire that assesses the presence and severity of depressive symptoms.
It is made up of 9 items on a Likert scale that goes from 0 (not at all) to 3 (almost every day).
The evaluation consists of the sum of the scores of each item having a range of 0 to 27.
These scores are interpreted from 0 to 5 (mild), 6 to 10 (moderate), 11 to 15 (moderately severe) and 16 to 27. (severe).
Within its psychometric properties, the original version has a high internal consistency with a Cronbach's alpha of 0.86, while the Mexican version was 0.89.
|
4 weeks after starting treatment
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 4 weeks after starting treatment
|
Self-administered questionnaire that assesses sleep quality.
It is made up of 24 reagents; the total score has a range of 0 to 21 points; where a total score less than 5 points indicates good sleep quality and a score greater than 5 points is interpreted as poor sleep quality.
In the Mexican population, he obtained a Cronbach's Alpha of 0.78.
|
4 weeks after starting treatment
|
Insomnia Severity Index (ISI)
Time Frame: 4 weeks after starting treatment
|
Self-administered questionnaire of 8 items on a Likert scale from 0 (none) to 4 (Very severe), which assesses nighttime symptoms, sleep quality, and daytime symptoms of insomnia; it has a reliability of 0.82 in its original version; and it has similar psychometric indicators in a version validated in Spanish.
In its version for the Mexican population, it obtained a 0.84 reliability coefficient.
|
4 weeks after starting treatment
|
SF-36 Health Survey
Time Frame: 4 weeks after starting treatment
|
It is a self-applicable instrument that evaluates the quality of life of people, it is divided into 8 dimensions associated with health such as: physical function, physical role, bodily pain, general health, vitality, social function, emotional role and mental health.
Each of these dimensions is evaluated in a different way, being a Likert scale between 4 and 5 response options and dichotomous (yes/no) in others.
Within the Mexican version, the psychometric properties showed a high internal consistency with a Cronbach's alpha of 0.93.
|
4 weeks after starting treatment
|
Generalized Anxiety Disorder 7 (GAD-7)
Time Frame: 4 weeks after starting treatment
|
Self-administered questionnaire that assesses the presence and severity of generalized anxiety symptoms.
It is made up of 7 items on a Likert scale that goes from 0 (not at all) to 3 (almost every day).
The evaluation consists of the sum of the scores of each item having a range from 0 to 21.
It is interpreted that a score greater than 10 is considered as generalized anxiety.
Within its psychometric properties, the version translated into Spanish has a high internal consistency with a Cronbach's alpha of 0.8.
|
4 weeks after starting treatment
|
Sleep diary
Time Frame: follow-up 3 months after the end of treatment
|
Self-registration format subjectively evaluates the number of sleepless nights, subjective sleep quality, number of awakenings per night, sleep onset latency, and sleep efficacy
|
follow-up 3 months after the end of treatment
|
Patient Health Questionnaire 9 (PHQ-9)
Time Frame: follow-up 3 months after the end of treatment
|
Self-applied questionnaire that assesses the presence and severity of depressive symptoms.
It is made up of 9 items on a Likert scale that goes from 0 (not at all) to 3 (almost every day).
The evaluation consists of the sum of the scores of each item having a range of 0 to 27.
These scores are interpreted from 0 to 5 (mild), 6 to 10 (moderate), 11 to 15 (moderately severe) and 16 to 27. (severe).
Within its psychometric properties, the original version has a high internal consistency with a Cronbach's alpha of 0.86, while the Mexican version was 0.89.
|
follow-up 3 months after the end of treatment
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: follow-up 3 months after the end of treatment
|
Self-administered questionnaire that assesses sleep quality.
It is made up of 24 reagents; the total score has a range of 0 to 21 points; where a total score less than 5 points indicates good sleep quality and a score greater than 5 points is interpreted as poor sleep quality.
In the Mexican population, he obtained a Cronbach's Alpha of 0.78.
|
follow-up 3 months after the end of treatment
|
Insomnia Severity Index (ISI)
Time Frame: follow-up 3 months after the end of treatment
|
Self-administered questionnaire of 8 items on a Likert scale from 0 (none) to 4 (Very severe), which assesses nighttime symptoms, sleep quality, and daytime symptoms of insomnia; it has a reliability of 0.82 in its original version; and it has similar psychometric indicators in a version validated in Spanish.
In its version for the Mexican population, it obtained a 0.84 reliability coefficient.
|
follow-up 3 months after the end of treatment
|
SF-36 Health Survey
Time Frame: follow-up 3 months after the end of treatment
|
It is a self-applicable instrument that evaluates the quality of life of people, it is divided into 8 dimensions associated with health such as: physical function, physical role, bodily pain, general health, vitality, social function, emotional role and mental health.
Each of these dimensions is evaluated in a different way, being a Likert scale between 4 and 5 response options and dichotomous (yes/no) in others.
Within the Mexican version, the psychometric properties showed a high internal consistency with a Cronbach's alpha of 0.93.
|
follow-up 3 months after the end of treatment
|
Generalized Anxiety Disorder 7 (GAD-7)
Time Frame: follow-up 3 months after the end of treatment
|
Self-administered questionnaire that assesses the presence and severity of generalized anxiety symptoms.
It is made up of 7 items on a Likert scale that goes from 0 (not at all) to 3 (almost every day).
The evaluation consists of the sum of the scores of each item having a range from 0 to 21.
It is interpreted that a score greater than 10 is considered as generalized anxiety.
Within its psychometric properties, the version translated into Spanish has a high internal consistency with a Cronbach's alpha of 0.8.
|
follow-up 3 months after the end of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Horacio B Álvarez García, M.D, Sleep Disorder Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 23, 2023
Primary Completion (Estimated)
December 20, 2023
Study Completion (Estimated)
February 1, 2024
Study Registration Dates
First Submitted
June 22, 2023
First Submitted That Met QC Criteria
July 10, 2023
First Posted (Actual)
July 19, 2023
Study Record Updates
Last Update Posted (Actual)
July 19, 2023
Last Update Submitted That Met QC Criteria
July 10, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HGMexico
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The database will be kept by the researchers and will be shared with other researchers upon request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
Clinical Trials on Brief Behavioral Intervention in Insomnia
-
Brigham and Women's HospitalRecruiting
-
VA Pittsburgh Healthcare SystemVA Office of Research and DevelopmentCompleted
-
National Cheng-Kung University HospitalRecruitingOlder Adults | Chronic Insomnia | Sleep HygieneTaiwan
-
Johns Hopkins UniversityRecruitingInsomnia | Substance Use DisordersUnited States
-
Brigham and Women's HospitalHarvard Medical School (HMS and HSDM)CompletedQuality of Life | Pain | Insomnia | SleepUnited States
-
VA Pittsburgh Healthcare SystemCompletedInsomnia | Treatment Resistant DepressionUnited States
-
University of PittsburghNational Institute of Mental Health (NIMH)CompletedChronic InsomniaUnited States
-
Minneapolis Veterans Affairs Medical CenterWithdrawn
-
Florida State UniversityNational Institute on Drug Abuse (NIDA)CompletedInsomnia | Substance Use Disorders | Posttraumatic Stress DisorderUnited States
-
Universidad Santo Tomas, ChileUniversidad de ConcepcionCompletedDepressive Symptoms | Posttraumatic Stress Disorder | Acute Post-Traumatic Stress DisorderChile